I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as filled class mail in an envelope addressed to:

Commissioner for Patents
Washington, D.C. 20231

on July 8 h, 2002

Date of Deposit

John Murray

Name of applicant, assignee or

Registered Representative

Signature
JULY 8th
Date of Signature

RECEIVED
JUL 1 7 2002

TECH CENTER 1600/2900

#8

Our Case No. 8642/94

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Nabel et al.

Serial No.: 09/708,276

Filing Date: Nov 7th, 2000

For:

Method for Treating Vascular

Proliferative Diseases with p27 and

Fusions Thereof

Group Art Unit No.: 1636

Examiner: Sandals, William O

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record.

)7/16/2002 NHDHANH1 00000047 09708276

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

It is believed that this Information Disclosure Statement is being filed after the mailing of a first Office Action on the merits but before the mailing date of a final Office Action. The fee required under 37 C.F.R. § 1.97(p) is included. However, should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the following cited documents are enclosed:

B1	U.S. 6,355,774	Mar 12, 2002	Massague et al.
B2	U.S. 6,316,208	Nov 13, 2001	Roberts et al.
B3	U.S. 6,242,575	Jun 5, 2001	Massague et al.
B4	U.S. 5,688,665	Nov 18, 1997	Massague et al.
B5	Craig et al. Proc. Annu. Meet. Assoc. Cancer Res. 37: A13 "Effects of a Recombinant Adenovirus Vector Expressing p27 on Cell Growth, Cell Cycle, Cyclin Kinases and Apoptosis"		



Respectfully submitted,

Date: July 8th, 2002

John Murray, Ph.D.
Registration No. 44,251
Attorney for Applicant

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200